{"nctId":"NCT04620135","briefTitle":"Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2020-11-30","type":"ACTUAL"},"conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"count":245,"armGroups":[{"label":"Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle","type":"EXPERIMENTAL","interventionNames":["Drug: Netarsudil ophthalmic solution 0.02%"]},{"label":"Ripasudil hydrochloride hydrate ophthalmic solution 0.4%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ripasudil hydrochloride hydrate ophthalmic solution 0.4%"]}],"interventions":[{"name":"Netarsudil ophthalmic solution 0.02%","otherNames":["Vehicle: Netarsudil ophthalmic solution"]},{"name":"Ripasudil hydrochloride hydrate ophthalmic solution 0.4%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 20 years of age or older\n* Diagnosis of POAG or OHT in both eyes (POAG in one eye and OHT in the fellow eye was acceptable)\n* Medicated intraocular pressure (IOP) ≥ 14 mmHg in at least one eye and \\< 30 mmHg in both eyes at screening visit\n* For POAG eyes, unmedicated (post washout) IOP ≥ 15 mmHg and \\< 35 mmHg in the study eye at 2 qualification visits (09:00 hours), 2-7 days apart. At second qualification visit IOP ≥ 15 mmHg and \\< 35 mmHg at 11:00 and 16:00 hour (in the same eye).\n* For OHT eyes, unmedicated (post washout) IOP ≥ 22 mmHg and \\< 35 mmHg in the study eye at 2 qualification visits (09:00 hours), 2-7 days apart. At second qualification visit IOP ≥ 22 mmHg and \\< 35 mmHg at 11:00 and 16:00 hours (in the same eye)\n* Best-corrected visual acuity (BCVA) +0.7 log MAR or better (20/100 Snellen or better or 0.20 or better in decimal unit) in each eye\n* Willingness and ability to give signed informed consent and follow study instructions\n\nExclusion Criteria:\n\n* Clinically significant ocular disease\n* Retinal diseases that may progress during the study period\n* Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles\n* Previous glaucoma intraocular surgery\n* Refractive surgery in either eye\n* Ocular hyperemia score of moderate (+2) or severe (+3) at Qualification Visit #2\n* Ocular trauma\n* Ocular infection or inflammation\n* Any corneal disease that may confound assessment\n* Evidence of corneal deposits or cornea verticillata\n* Known hypersensitivity to any component of netarsudil ophthalmic solution 0.02%, ripasudil hydrochloride hydrate ophthalmic solution 0.4%, or to topical anesthetic.\n* Mean central corneal thickness \\>620 um\n* Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g. keratoconus)\n* Cannot demonstrate proper delivery of the eye drop\n* Clinically significant systemic disease\n* Participation in any investigational study within 30 days prior to screening\n* Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intraocular Pressure (IOP)","description":"Comparison of both groups mean diurnal IOP at Week 4 (Day 29). IOP will be measured by Goldmann applanation tonometry and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Mean diurnal IOP was calculated as the average of 3 IOP values across 09:00, 11:00 and 16:00 time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.96","spread":"0.157"},{"groupId":"OG001","value":"17.71","spread":"0.155"}]}]}]},{"type":"SECONDARY","title":"IOP at Weeks 1 and 2","description":"Mean diurnal IOP as measured in mmHg at each post-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.28","spread":"0.143"},{"groupId":"OG001","value":"17.87","spread":"0.141"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.02","spread":"0.168"},{"groupId":"OG001","value":"17.83","spread":"0.166"}]}]}]},{"type":"SECONDARY","title":"Mean Change IOP From Baseline at Days 8, 15, 29","description":"Mean change from baseline in mean diurnal IOP as measured in mmHg at each post-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.475","spread":"0.2510"},{"groupId":"OG001","value":"20.830","spread":"0.3198"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.341","spread":"0.1603"},{"groupId":"OG001","value":"-2.814","spread":"0.1397"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.601","spread":"0.1728"},{"groupId":"OG001","value":"-2.852","spread":"0.1759"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.653","spread":"0.1701"},{"groupId":"OG001","value":"-2.983","spread":"0.1622"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":122},"commonTop":["Conjunctival hyperaemia","Eye irritation"]}}}